U3 Pharma GmbH

Company

    • Company type:
      • Manufacturer
    • Year founded:
    • 2001
    • Employees (at the site):
    • 18
    • Turnover range:
    • 5m - <10m EUR
    • Products/services:
    • Drug Development, Antibody, Small Molecules

    • Core competencies:
    • U3 Pharma AG focusses on the development of signal transduction specific therapeutics for the treatment of hyperproliferative diseases in particular cancer. U3 is developing both monoclonal antibodies and small molecules against a series of proprietary targets that have been in-licensed from the Max Planck Society. To date, U3 has entered into two collaborations: with Abgenix Inc. of Fremont, USA and EvotecOAI AG of Hamburg, Germany in order to enable the rapid creation and development of best-in-class therapeutics. Founded by Axel UIlrich in 2001, U3 currently employs 18 people - 11 of whom are PhDs at its state-of-the-art laboratories in Munich, Germany. Alta Partners of San Francisco, USA lead U3´s first round of financing and were joined by BioM and private investors. U3's second round of financing was closed in August 2003 and was co-led by Atlas Venture and LCF Rothschild Venture Partners.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72.19: Other research and experimental development on natural sciences and engineering
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Johannes Bange (Mr.)
      - Management